- ￥6768
- AntibodySystem
- 62.5 - 4,000 ng/mL
- 64.37 ng/mL
- France
- KDB95601
- 2025年12月21日
9 年钻石会员
企业认证
相关产品推荐更多 >
大鼠补体成分3(C3)酶联免疫吸附测定试剂盒 | Rat C3(Complement 3) ELISA Kit
￥2300人基质金属蛋白酶10(MMP-10)酶联免疫吸附测定试剂盒 | Human MMP-10(Matrix Metalloproteinase 10) ELISA Kit
￥2300人P选择素(SELP)酶联免疫吸附测定试剂盒 | Human SELP(P-Selectin) ELISA Kit
￥1800
微量法小鼠巨噬细胞来源的趋化因子(MDC/CCL22)酶联免疫吸附测定试剂盒 | Mini Sample Mouse ADP/Acrp30 (Adiponectin) ELISA Kit
￥2180人胰岛素样生长因子2(IGF-2)酶联免疫吸附测定试剂盒 | Human IGF-2(Insulin Like Growth Factor 2) ELISA Kit
￥2300
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 供应商：
武汉益普生物科技有限公司
- 检测范围：
62.5 - 4,000 ng/mL
- 检测方法：
Colorimetric
- 样本：
Plasma, Serum
- 灵敏度：
64.37 ng/mL
- 规格：
96T
| 产品名 | Canakinumab ELISA Kit |
| 货号 | KDB95601 |
| 规格 | 96T |
| 别名 | ACZ885, CAS: 914613-48-2 |
| 应用 | Used for the quantitative determination of Canakinumab concentration in serum and plasma. |
| 检测方法 | Colorimetric |
| 样本类型 | Plasma, Serum |
| 实验类型 | Quantitative |
| 检测范围 | 62.5 - 4,000 ng/mL |
| 灵敏度 | 64.37 ng/mL |
| 回收率 | 80-120% |
| 精准度 | CV<20% |
| 描述 | PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL1B has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Canakinumab in the sample competitively binds to the pre-coated protein with biotin-labeled Canakinumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Canakinumab bound in the initial step. The color development is stopped and the intensity of the color is measured. |
| 背景 | Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of familial cold auto-inflammatory syndrome and Muckle-wells syndrome, which are inflammatory diseases related to cryopyrin-associated periodic syndromes. The drug is currently being evaluated for its potential in the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, chronic obstructive pulmonary disease, type 1 and 2 diabetes and ocular diseases. Reports from clinical trials suggest that canakinumab is well-tolerated in most patients, and no serious adverse effects have been reported. The drug provides significant advantages over existing competitive therapies, including bimonthly administration and approved use in children. |
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 保存方法 | 2-8 ℃ |
| 说明 | For Research Use Only. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
Canakinumab ELISA Kit（ELISA试剂盒）
￥6768
